<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780725</url>
  </required_header>
  <id_info>
    <org_study_id>1381-0003</org_study_id>
    <secondary_id>2017-005046-30</secondary_id>
    <nct_id>NCT03780725</nct_id>
  </id_info>
  <brief_title>This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091</brief_title>
  <official_title>An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 754111 in Patients With Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma Treated With BI 754111 in Combination With BI 754091</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the biodistribution and intra-tumor
      accumulation of [89Zr]Zr-BI 754111 at baseline and its change upon treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake values (SUVs) of [89Zr]Zr-BI 754111 for tumor uptake</measure>
    <time_frame>Up to 29 days post-baseline</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 followed by Part 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754111</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754091</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written Informed Consent Form (ICF) prior to any trial
             specific procedures, sampling, or analyses

          -  Patients of legal age (according to local legislation) at the time of signature of the
             ICF

          -  Patients with histologically confirmed diagnosis of recurrent NSCLC who received anti-
             PD-1 or anti PD-L1 as Part of last treatment with at least 3 months of stable disease
             (i.e.patients with confirmed response (PR or CR) regardless of duration of response or
             stable disease (SD) for a minimum of 3 months) and have become refractory to anti-PD-
             1/ anti-PD-L1 based treatment OR

             --Patients with histologically confirmed diagnosis of recurrent metastatic HNSCC who
             progressed after platinum based therapy or not indicated for receiving standard
             (radio) chemotherapy (previous treatment with anti- PD-1/ PD-L1 is allowed)

          -  Eastern Cooperative Oncology Group (ECOG, R01-0787) score: 0 to 1

          -  Patient must have at least one PET imageable and evaluable tumor lesion of 20mm

          -  Patients must have at least one tumor lesion amenable to biopsy. This lesion should be
             PET imageable and evaluable as defined above and the biopsy should be obtained before
             first BI 754091 administration, unless medically contra-indicated. In the latter case,
             25 4Î¼m sections from an archival biopsy taken at relapse after the previous treatment
             are acceptable

          -  Must have evaluable lesion(s) according to Revised Response Evaluation Criteria in
             Solid Tumors (RECIST) Version 1.1 and iRECIST

          -  Life expectancy of at least 12 weeks after the start of the treatment according to the
             Investigator's judgement

          -  Male or female patients. Women of childbearing potential (WOCBP)1 and men able to
             father a child must be ready and able to use highly effective methods of birth control
             per International Conference on Harmonisation (ICH) M3 (R2) (that result in a low
             failure rate of less than 1% per year when used consistently and correctly) during
             trial Participation and for at least 6 months after the last administration of trial
             medication. A list of contraception methods meeting these criteria is provided in the
             patient information.

        Exclusion Criteria:

          -  Not having fully recovered from major surgery before they enter into the trial
             according to investigator judgment or planned for major surgery within 12 months after
             screening, e.g. hip replacement

          -  Patients who must or wish to continue the intake of restricted medications or any drug
             considered likely to interfere with the safe conduct of the trial

          -  Patients not expected to comply with the protocol requirements or not expected to
             complete the trial as scheduled

          -  Previous treatment in this trial

          -  Any investigational or anti-tumor treatment within 4 weeks or within 5 half-life
             periods (whichever is shorter) prior to the initiation of trial treatment.

          -  Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of
             starting study treatment with the exception of alopecia and Grade 2 neuropathy due to
             prior platinum-based therapy

          -  Prior treatment with anti-LAG-3 agents

          -  Presence of other active invasive cancers other than the one treated in this trial,
             with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or
             carcinoma in situ of the cervix, or other local tumors considered cured by local
             treatment

          -  Untreated brain metastasis(es) that may be considered active. Patients with previously
             treated brain metastases may Participate provided they are stable (i.e., without
             evidence of PD by imaging for at least 4 weeks prior to the first dose of trial
             treatment, and any neurologic symptoms have returned to baseline), and there is no
             evidence of new or enlarging brain metastases

          -  Inadequate organ function or bone marrow reserve as demonstrated by the laboratory
             values

          -  Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (QTc) &gt;470 msec

               -  Any clinically important abnormalities in rhythm, conduction, or morphology of
                  resting ECGs, e.g., complete left bundle branch block, third degree heart block

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, hypokalaemia, congenital long QT syndrome, family
                  history of long QT syndrome or unexplained sudden death under 40 years-of-age, or
                  any concomitant medication known to prolong the QT interval

               -  Ejection fraction &lt;55% or the lower limit of normal of the institutional
                  standard.

          -  History of pneumonitis within the last 5 years

          -  History of severe hypersensitivity reactions to other mAbs

          -  Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within
             4 weeks prior to the first dose of study treatment.

          -  Active autoimmune disease or a documented history of autoimmune disease, except
             vitiligo or resolved childhood asthma/atopy

          -  Active infection requiring systemic treatment (antibacterial, antiviral, or antifungal
             therapy) at start of treatment in this trial

          -  Known history of human immunodeficiency virus infection or an active hepatitis B or C
             virus infection

          -  Interstitial lung disease

          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,
             makes him/her an unreliable trial patient or unlikely to complete the trial or unable
             to comply with the protocol procedures

          -  Women who are pregnant, nursing, or who plan to become pregnant in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam UMC Locatie VUMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Idris Bahce</last_name>
      <phone>+31 (0)20-4444444</phone>
      <email>i.bahce@amsterdamumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
Studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

